Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis

Inclusion Criteria: * Patients diagnosed with endogenous anterior uveitis or panuveitis * Patients with 10 - 49 anterior chamber cells within one field of the anterior chamber as observed by slit lamp microscopy (criterion for rating of signs 2 or 3) * Patients aged ‰1425 years (on the day of obtaining informed consent) who were able to accurately express their own symptoms * Patients provided written informed consent prior to initiation of the study Exclusion Criteria: * Patients who did not meet all of the above inclusion criteria * Patients received systemic administration of any corticosteroid or immunosuppressive drug within the past 1 week prior to instillation of the investigational product * Patients received topical injection of any corticosteroid in eyes prior to instillation of the investigational product (Solution formulation: within the past 1 week, depot: within the past 2 weeks) * Patients received systemic administration of any non-steroidal anti-inflammatory drug or antiphlogistic enzyme within the past 3 days prior to instillation of the investigational product * Patients received instillation of any corticosteroid, non-steroidal anti-inflammatory drug or antiphlogistic enzyme within 12 hours prior to instillation of the investigational product * Patients with glaucoma or ocular hypertension * Patients with corneal abrasion or ulcer * Patients with any confirmed or suspected viral, bacterial or fungal keratoconjunctival disease * Patients with allergy to similar drugs such as other corticosteroids * Patients requiring use of contact lens during the study period * Women who are or might be pregnant, or lactating women * Patients participating in another clinical study within the past 3 months before initiation of the present study